Progression-free survival (IRC)
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Shuhua Yi, Jiang Cao, Ru Feng, Keshu Zhou, Lihua Qiu, Fei Li, Hai Yan Yang, Hui Zhou, Wuhan Hui, Jie Cui, He Huang, Jiankun Zhu, Xiuhui Ye, Jeff Sharman, Lugui Qiu
Br J Haematol 208(3) 926-936
BRUIN CLL-321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression-free survival (PFS) compared to investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BendaR). This report presents results from Chinese patients enrolled in BRUIN CLL-321, who were randomized 1:1 to pirtobrutinib (200 mg once daily) or IC of BendaR (idelalisib is not approved in China). End-points included independent review committee (IRC)-assessed PFS, investigator (INV)-assessed PFS, overall survival (OS), event-free survival (EFS), time to next treatment (TTNT) and safety. Among 40 Chinese patients (pirtobrutinib n = 19; BendaR n = 21), IRC-assessed PFS favoured pirtobrutinib (stratified hazard ratio [HR] = 0.281; 95% confidence interval [CI], 0.070-1.125, nominal p = 0.0554), with median PFS not reached versus 10.6 months with BendaR; INV-assessed PFS supported these findings. TTNT (HR = 0.150; 95% CI, 0.031-0.728) and EFS (HR = 0.322; 95% CI, 0.094-1.101) were also improved. A trend towards OS benefit was observed (HR = 0.343; 95% CI, 0.031-3.787). Pirtobrutinib showed a favourable safety profile, with fewer grade ≥3 treatment-emergent adverse events (36.8% vs. 93.3%) and serious adverse events (15.8% vs. 46.7%). These findings support pirtobrutinib as a clinically active and tolerable option for cBTKi-pretreated Chinese CLL/SLL population.
4 个 Figure · 5 个 KM 面板
FIGURE 2 Kaplan–Meier curve of PFS as assessed by (A) IRC and (B) Investigator. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; IRC, independent review committee; NR, not reached; PFS, progression‐free survival.
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel B
Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 Kaplan–Meier curve of overall survival. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; NR, not reached.
FIGURE 3 · Panel Overall_survival
Panel Overall_survival 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 4 Kaplan–Meier curve of time to next treatment. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; NR, not reached.
FIGURE 4 · Panel Time_to_next_treatment
Panel Time_to_next_treatment 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 Kaplan–Meier curve of event‐free survival. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; NR, not reached.
FIGURE 5 · Panel Event-free_survival_curve
Panel Event-free_survival_curve 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。